RxDoctor Payments Data

Antonio Sanchez, MD

Hepatology · Iowa City, IANPI 1467441238

Payments from drug & device makers

$1,549,524in general payments, 2019–2025

Across 436 payments — averaging $3553.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$446K
  • Boehringer Ingelheim$288K
  • Bausch Health US, LLC$209K
  • GSK$200K
  • Takeda Pharmaceuticals U.S.A., Inc.$114K
  • Merck$77K
  • plus $215K from 8 others
$1,775in research payments, 2019–2025

Across 3 payments — averaging $591.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$2K

What the payments were for

  • Speaking & faculty fees$24,29688%
  • Travel & lodging$1,2314%
  • Food & beverage$2,1928%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$29,316
Medicare patients
164
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin124$435,864
Everolimus35$60,767
Ursodiol168$24,164
PrografTacrolimus20$19,729
Tacrolimus219$10,981
Sirolimus11$5,172
Cyclosporine ModifiedCyclosporine, Modified24$2,535
Mycophenolate Mofetil30$2,046
Entecavir13$1,907
Azathioprine63$1,827
Lactulose57$1,312
Spironolactone80$1,022
Colestipol Hcl15$907
Ciprofloxacin Hcl60$648
Prednisone63$493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$73$435,864124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other hepatology in Iowa City

Where these figures come from

Is this you, or does something look wrong? →